12/25
12:39 pm
mnmd
Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026 [Yahoo! Finance]
Medium
Report
Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026 [Yahoo! Finance]
12/23
08:57 am
mnmd
Mind Medicine (MindMed) (NASDAQ:MNMD) is now covered by analysts at Jones Trading. They set a "buy" rating and a $61.00 price target on the stock.
Medium
Report
Mind Medicine (MindMed) (NASDAQ:MNMD) is now covered by analysts at Jones Trading. They set a "buy" rating and a $61.00 price target on the stock.
12/19
11:37 am
mnmd
Psychedelics stocks could benefit from marijuana rescheduling: Jefferies [Seeking Alpha]
Low
Report
Psychedelics stocks could benefit from marijuana rescheduling: Jefferies [Seeking Alpha]
12/19
07:26 am
mnmd
Assessing Mind Medicine (MNMD)'s Valuation After Strong Multi-Year Share Price Gains [Yahoo! Finance]
Low
Report
Assessing Mind Medicine (MNMD)'s Valuation After Strong Multi-Year Share Price Gains [Yahoo! Finance]
12/18
07:01 am
mnmd
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/15
04:01 pm
mnmd
MindMed Announces New Employee Inducement Grant
Low
Report
MindMed Announces New Employee Inducement Grant
12/1
04:01 pm
mnmd
MindMed Announces New Employee Inducement Grants
Low
Report
MindMed Announces New Employee Inducement Grants
11/21
05:31 am
mnmd
Mind Medicine (MindMed) (NASDAQ:MNMD) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Low
Report
Mind Medicine (MindMed) (NASDAQ:MNMD) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/7
04:57 pm
mnmd
Mind Medicine (MindMed) (NASDAQ:MNMD) had its price target raised by analysts at Canaccord Genuity Group Inc. from $16.00 to $25.00. They now have a "buy" rating on the stock.
Low
Report
Mind Medicine (MindMed) (NASDAQ:MNMD) had its price target raised by analysts at Canaccord Genuity Group Inc. from $16.00 to $25.00. They now have a "buy" rating on the stock.
11/7
02:22 pm
mnmd
Mind Medicine (MindMed) (NASDAQ:MNMD) had its price target lowered by analysts at Royal Bank Of Canada from $21.00 to $20.00. They now have an "outperform" rating on the stock.
Medium
Report
Mind Medicine (MindMed) (NASDAQ:MNMD) had its price target lowered by analysts at Royal Bank Of Canada from $21.00 to $20.00. They now have an "outperform" rating on the stock.
11/7
12:20 am
mnmd
Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... [Yahoo! Finance]
Medium
Report
Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... [Yahoo! Finance]
11/6
04:01 pm
mnmd
MindMed Reports Q3 2025 Financial Results and Business Updates
Medium
Report
MindMed Reports Q3 2025 Financial Results and Business Updates
11/5
07:01 am
mnmd
MindMed to Participate in Upcoming Investor Conferences
Medium
Report
MindMed to Participate in Upcoming Investor Conferences
11/3
04:01 pm
mnmd
MindMed Announces New Employee Inducement Grant
Low
Report
MindMed Announces New Employee Inducement Grant
11/3
07:01 am
mnmd
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
High
Report
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
10/30
04:01 pm
mnmd
MindMed to Report Q3 2025 Financial Results on November 6, 2025
Medium
Report
MindMed to Report Q3 2025 Financial Results on November 6, 2025
10/29
10:14 pm
mnmd
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
Medium
Report
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
10/29
04:01 pm
mnmd
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
Medium
Report
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
10/25
12:09 pm
mnmd
Mind Medicine (MindMed) (NASDAQ:MNMD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Mind Medicine (MindMed) (NASDAQ:MNMD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/18
05:30 pm
mnmd
MindMed (MNMD): Assessing Valuation After MM120's Breakthrough Results and Phase 3 Advances [Yahoo! Finance]
Medium
Report
MindMed (MNMD): Assessing Valuation After MM120's Breakthrough Results and Phase 3 Advances [Yahoo! Finance]
10/15
07:11 am
mnmd
Mind Medicine (MindMed) (NASDAQ:MNMD) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Low
Report
Mind Medicine (MindMed) (NASDAQ:MNMD) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
10/14
04:01 pm
mnmd
MindMed Announces New Employee Inducement Grant
Low
Report
MindMed Announces New Employee Inducement Grant
10/14
07:59 am
mnmd
Mind Medicine (MindMed) (NASDAQ:MNMD) was upgraded by analysts at Needham & Company LLC to a "moderate buy" rating.
Medium
Report
Mind Medicine (MindMed) (NASDAQ:MNMD) was upgraded by analysts at Needham & Company LLC to a "moderate buy" rating.
10/13
07:04 am
mnmd
Mind Medicine (MindMed) (NASDAQ:MNMD) was given a new $28.00 price target on by analysts at Needham & Company LLC.
Low
Report
Mind Medicine (MindMed) (NASDAQ:MNMD) was given a new $28.00 price target on by analysts at Needham & Company LLC.
9/30
08:04 pm
mnmd
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) high institutional ownership speaks for itself as stock continues to impress, up 26% over last week [Yahoo! Finance]
Medium
Report
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) high institutional ownership speaks for itself as stock continues to impress, up 26% over last week [Yahoo! Finance]